Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the efficacy in terms of clinical and biological
response rates of Cladribine plus Pegylated Interpheron alpha-2a therapy in patients with
advanced systemic mastocytosis carrying D816V or other exon 17 KIT mutations.